News Focus
News Focus
Replies to #96142 on Biotech Values
icon url

Bio_pete

05/21/10 8:10 AM

#96143 RE: DewDiligence #96142

BPAX - The mention of DNDN with the restart of the GVAX program was sleazy, but I don't see anything wrong with yesterdays PR. Licensing the 2A/Furin technology may be worth a significant amount for all we know.

I'm pretty wary of BPAX, but in this instance I'll give them a pass. It looks like they have at least two parties evaluating the technology.